Sunshine Biopharma Inc. announced it has developed an orally active protease inhibitor that showed dose-dependent antiviral activity in mice infected with SARS-CoV-2.
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
The Agency for Science Technology & Research (A*STAR) Bioprocessing Technology Institute has patented 3C-like proteinase (3CLpro; Mpro; nsp5) (coronavirus) inhibitors.
Westlake Pharmaceutical (Hangzhou) Co. Ltd. has prepared and tested new 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
One of the challenges associated with COVID-19 has been an increase of secondary infections, including fungal infections. These coinfections can hinder treatment efficacy and increase illness severity.
The COVID-19 pandemic pushed the urgency for effective antiviral drugs against coronaviruses. Researchers from Europe conducted machine learning and in vitro validation experiments for the identification of potential antiviral drugs effective against coronaviruses.
Tohoku University has disclosed 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections and inflammatory disorders.